Regulatory Filings • Mar 17, 2022
Regulatory Filings
Open in ViewerOpens in native device viewer
Bergen, Norway, 17 March 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, is pleased to announce that CEO Martin Olin will be presenting at the Carnegie Virtual Nordic Healthcare Seminar taking place today at 15:15 CET.
The presentation will be made available on the Company's website in the Investors section shortly after the presentation.
-Ends-
Martin Olin Chief Executive Officer, BerGenBio ASA [email protected]
Rune Skeie Chief Financial Officer, BerGenBio ASA [email protected]
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone Consilium Strategic Communications [email protected] +44 20 3709 5700
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially firstin-class selective AXL inhibitor in a broad phase II clinical development programme focused on combination and single agent therapy in cancer and COVID-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is developing a potential companion diagnostic test to identify patient populations most likely to benefit from AXL inhibition: this is expected to facilitate more efficient registration trials supporting a precision medicinebased commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.